Skip to main content

Table 2 Baseline characteristics of cohort 2 (RKD)

From: The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset

Characteristics

Total

GPA

MPA

EGPA

p

n (%)

439

196 (44.6)

220 (50.1)

23 (5.2)

 

Age (years, median [IQR])

59.0 [48.0, 69.0]

54.0 [40.0, 62.3]

65.0 [54.0, 73.0]

57.0 [51.5, 62.5]

< 0.001

Male (%)

253 (57.6)

112 (57.1)

129 (58.6)

12 (52.2)

0.823

Ethnicity (%)

    

0.353

 White

433 (98.6)

194 (99.0)

217 (98.6)

22 (95.7)

 

 Asian

6 (1.4)

2 (1.0)

3 (1.4)

1 (4.3)

 

ANCA subtype (ELISA) (%)

    

< 0.001

 PR3

219 (49.9)

170 (86.7)

45 (20.5)

4 (17.4)

 

 MPO

207 (47.2)

19 (9.7)

172 (78.2)

16 (69.6)

 

 ELISA-negative

12 (2.7)

6 (3.1)

3 (1.4)

3 (13.0)

 

 No ELISA recorded

1 (0.2)

1 (0.5)

0 (0.0)

0 (0.0)

 

Organ involvement (%)

 Musculoskeletal

168 (38.3)

103 (52.6)

53 (24.1)

12 (52.2)

< 0.001

 Mucocutaneous

115 (26.2)

71 (36.2)

34 (15.5)

10 (43.5)

< 0.001

 Eyes

57 (13.0)

37 (18.9)

18 (8.2)

2 (8.7)

0.004

 Lung

229 (52.2)

132 (67.3)

78 (35.5)

19 (82.6)

< 0.001

 Neurological

60 (13.7)

27 (13.8)

22 (10.0)

11 (47.8)

< 0.001

 Ears, nose, throat

193 (44.0)

147 (75.0)

29 (13.2)

17 (73.9)

< 0.001

 Cardiovascular

12 (2.7)

6 (3.1)

6 (2.7)

0 (0.0)

1

 Kidney

370 (84.3)

146 (74.5)

212 (96.4)

12 (52.2)

< 0.001

 Gastrointestinal

25 (5.7)

13 (6.6)

11 (5.0)

1 (4.3)

0.828

Latitude (degrees, median [IQR])

53.30 [52.67, 53.39]

53.29 [52.67, 53.39]

53.32 [52.76, 53.39]

53.29 [52.86, 53.37]

0.350

Longitude (degrees, median [IQR])

− 6.39 [− 7.77, − 6.30]

− 6.43 [− 8.37, − 6.27]

− 6.48 [− 8.35, − 6.22]

− 6.39 [− 7.77, − 6.30]

0.684

CW-D-UVB at symptom onset (kJ/m2, median [IQR])

75.98 [19.12, 161.06]

78.46 [20.29, 166.07]

74.57 [18.94, 153.51]

60.41 [30.27, 115.27]

0.842

Season of diagnosis (%)

    

0.502

 Spring

129 (29.4)

60 (30.6)

67 (30.5)

2 (8.7)

 

 Summer

92 (21.0)

41 (20.9)

44 (20.0)

7 (30.4)

 

 Autumn

112 (25.5)

48 (24.5)

57 (25.9)

7 (30.4)

 

 Winter

106 (24.1)

47 (24.0)

52 (23.6)

7 (30.4)

 

Follow-up (months, median [IQR])

58.3 [32.1, 138.1]

84.7 [39.5, 183.9]

45.4 [26.0, 83.8]

108.4 [49.8, 160.2]

< 0.001

Death (%)

38 (8.7)

11 (5.6)

25 (11.4)

2 (8.7)

0.112

Number of patients experiencing n relapse(s) (%)

 0

343 (78.1)

141 (71.9)

188 (85.5)

14 (60.9)

 

 1

67 (15.3)

37 (18.9)

26 (11.8)

4 (17.4)

 

 2

20 (4.6)

12 (6.1)

4 (1.8)

4 (17.4)

 

 3

8 (1.8)

5 (2.6)

2 (0.9)

1 (4.3)

 

 4

1 (0.2)

1 (0.5)

0 (0)

0 (0)

 
  1. Refer to supplementary materials for the definitions of ‘date of symptom onset’ and seasons. Refer to Additional file 1: Table S1 for the details on the induction and maintenance treatment. Continuous variables are reported as mean (standard deviation (SD)) or median (interquartile range (IQR)) if not normally distributed and compared using the independent sample t-test or the Mann-Whitney U test, respectively. Categorical variables are summarised by frequency and percentage (%) and compared using the χ2 test
  2. ANCA anti-neutrophil cytoplasmic antibodies, ELISA enzyme-linked immunoassay, PR3 proteinase-3, MPO myeloperoxidase, CW-DUVB cumulative-weighted UVB dose, SD standard deviation, IQR inter-quartile range